Uterine Cancer pp 417-423 | Cite as

Endometrial Cancers in Young Women: Conservative Management and Fertility Preserving Options

  • Bindiya Gupta
  • Shalini Rajaram


Endometrial cancer is increasingly being diagnosed in women <40 years. Around 1.6 % cases occur between 20 and 34 year age and 6 % between 35 and 44 years of age according to the SEER statistics [1]. A woman under the age of 40 has a 1 in 1423 risk of developing endometrial cancer [2]. Genetic predisposition and conditions with estrogen excess are the main risk factors. Women <40 years, with well differentiated stage 1a cancer can be offered conservative management after appropriate counseling and investigative work-up. Progestins form the mainstay of treatment in addition to other novel strategies. Pregnancy rates of 30-40% have been reported after conservative management.


Endometrial Cancer Lynch Syndrome Megestrol Acetate Myometrial Invasion Medroxyprogesterone Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Howlader N et al. SEER cancer statistics review, 1975–2008. 2011 [cited 2011; based on Nov 2010 SEER data submission]. Available from:
  2. 2.
    Siegel R, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol. 2007;46:26–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Smith RA, von Eschenbach AC, Wender R et al; ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, ACS Endometrial Cancer Advisory Committee. American Cancer Society Guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA Cancer J Clin. 2001;51(1):38–75.Google Scholar
  5. 5.
    Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer: a gynecologic oncology group study. Cancer. 1987;60:2035–41.CrossRefPubMedGoogle Scholar
  6. 6.
    Zaino R, Whitney C, Brady MF, et al. Simultaneously detected endometrial and ovarian carcinomas: a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol. 2001;83:355–62.CrossRefPubMedGoogle Scholar
  7. 7.
    Walsh C, Holschneider C, Hoang Y, et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005;106:693–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Navarria I, Usel M, Rapiti E, et al. Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment? Gynecol Oncol. 2009;114:448–51.CrossRefPubMedGoogle Scholar
  9. 9.
    Arora V, Quinn MA. Endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2012;26(3):311–24.CrossRefPubMedGoogle Scholar
  10. 10.
    Lee WL, Lee FK, Su WH, et al. Hormone therapy for younger patients with endometrial cancer. Taiwan J Obstet Gynecol. 2012;51(4):495–505.CrossRefPubMedGoogle Scholar
  11. 11.
    Mazur MT. Endometrial hyperplasia/adenocarcinoma. A conventional approach. Ann Diagn Pathol. 2005;9:174–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Dreisler E, Poulsen LG, Antonsen SL et al; European Menopause and Andropause Society. EMAS clinical guide: assessment of the endometrium in peri and postmenopausal women. Maturitas 2013;75(2):181–90.Google Scholar
  13. 13.
    Leitao Jr MM, Kehoe S, Barakat RR, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol. 2009;113:105–8.CrossRefPubMedGoogle Scholar
  14. 14.
    van Dongen H, de Kroon CD, Jacobi CE, Trimbos JB, Jansen FW. Diagnostic hysteroscopy in abnormal uterine bleeding: a systematic review and metaanalysis. BJOG. 2007;114(6):664–75.CrossRefPubMedGoogle Scholar
  15. 15.
    Ceci O, Bettocchi S, Pellegrino A, Impedovo L, Di VR, Pansini N. Comparison of hysteroscopic and hysterectomy findings for assessing the diagnostic accuracy of office hysteroscopy. Fertil Steril. 2002;78(3):628–31.CrossRefPubMedGoogle Scholar
  16. 16.
    Kaneda S, Fujii S, Fukanaga T, et al. Myometrial invasion by endometrial carcinoma: evaluation with 3.0T MR imaging. Abdom Imaging. 2011;36:612–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Vasconcelos C, Félix A, Cunha TM. Preoperative assessment of deep myometrial and cervical invasion in endometrial carcinoma: comparison of magnetic resonance imaging and histopathologic evaluation. J Obstet Gynaecol. 2007;27:65–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Selman TJ, Mann CH, Zamora J, et al. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health. 2008;8:8.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Horowitz NS, Dehdashti F, Herzog TJ, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol. 2004;95:546–51.CrossRefPubMedGoogle Scholar
  20. 20.
    Tong XM, Lin XN, Jiang HF, Jiang LY, Zhang SY, Liang FB. Fertility-preserving treatment and pregnancy outcomes in the early stage of endometrial carcinoma. Chin Med J. 2013;126(15):2965–71.PubMedGoogle Scholar
  21. 21.
    Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011;22:145–52.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Hahn H-S, Yoon S-G, Hong J-S, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009;19:1068–73.CrossRefPubMedGoogle Scholar
  23. 23.
    Corfman PA. Labeling guidance text for progestin-only oral contraceptives. Contraception. 1995;52:71–6.CrossRefGoogle Scholar
  24. 24.
    Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186:651–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Kudesia R, Singer T, Caputo TA, et al. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma. Am J Obstet Gynecol. 2014;210:255.e1–4.CrossRefGoogle Scholar
  26. 26.
    Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol. 2005;97:924–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125:477–82.CrossRefPubMedGoogle Scholar
  28. 28.
    Minig L, Franchi D, Boveri S, et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol. 2011;22:643–49.CrossRefPubMedGoogle Scholar
  29. 29.
    Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93:1286–89.CrossRefPubMedGoogle Scholar
  30. 30.
    Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25:2798–803.CrossRefPubMedGoogle Scholar
  31. 31.
    Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266.e1–12.CrossRefGoogle Scholar
  32. 32.
    Chi DS, Barakat RR, Palayekar MJ, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer. 2008;18:269–73.CrossRefPubMedGoogle Scholar
  33. 33.
    Richter CE, Qian B, Martel M, et al. Ovarian preservation and staging in reproductive-age endometrial cancer patients. Gynecol Oncol. 2009;114:99–104.CrossRefPubMedGoogle Scholar
  34. 34.
    Wright JD, Buck AM, Shah M, Burker WM, Schiff PR, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol. 2009;27:1214–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Elizur SE, Beiner ME, Korach J, Weiser A, Ben-Baruch G, Dor J. Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril. 2007;88:1562–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95:133–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Chiva L, Lapuente F, González-Cortijo L, Carballo N, García JF, Rojo A, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol. 2008;111(2 Suppl):S101–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Yamagami W, Susumu N, Ichikawa Y, et al. Thirty-four successful cases of pregnancy following fertility-preserving hormonal therapy for endometrial cancer. Gynecol Oncol. 2012;125:S5.CrossRefGoogle Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  1. 1.Department of Obstetrics & GynecologyUniversity College of Medical Sciences and Guru Teg Bahadur HospitalDelhiIndia

Personalised recommendations